Photocure $PHO.OL OSL:PHO presented Q2 2019 numbers today, with most numbers landing very close to expectations.
Press release: newsweb.oslobors.no
Armchair Healthcare podcast interview with CEO Dan Schneider: twitter.com
Investors are eagerly awaiting Photocures OSL:PHO Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal.
Also key is the information about the current growth rate on Cysview sales in US.
NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could...
Photocure OSL:PHO today released news of a outlicensing of the Cevira franchise for commercialization, giving the stock a boost, possibly regaining foothold above the SMA50 and SMA200.
Oslo (Norway), 2 May 2019 . PCI Biotech (OSL:PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the final immune response results from the fima_Vacc_ Phase I study in...
Photocure $PHO.OL approaching relevant resistance levels and a breakout to the upside could easily be triggered as the market cap of the company is still low.
Recent Edison analysis quote:
"Phenomenal US growth
Q418 sales in the US increased 81% to NOK18.4m and are up 50% over the course of 2018 with a clear acceleration in the second half of the year. Unit...
As mentioned in an earlier Idea ( ), the Q4 report represented a substantial risk for a downwards reaction after a recent surge in the share price.
At the new price level around NOK 41 the stock is much more attractively priced, and this could be the time...
In January, NEL Hydrogen finished a very successful large private offering at NOK 5.45 ( nelhydrogen.com ) , but both the technical uptrend and fundamentals remain solid, with the company set to invest the proceeds from the placement in rapidly scaling up production facilities.
Photocure stock reacted with a heavy (overdone?) correction after the Q3 report, but has recovered nicely in later weeks.
As mentioned in an earlier TradingView analysis (), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK...
BUY Signal: Any move on high volume punching through NOK 15 and especially NOK 16.5 represents renewed positive momentum in the FUNCOM stock.
The top 20 owner list in Funcom has been dominated by active traders selling off after the recent NOK 25 peak that occured after Funcom announced that...
With the #ASH18 conference getting closer, Nordic Nanovector has punched through the 2 year long downtrend from the ATH in December 2016.
CEO Eduardo Bravo presented at Jefferies 2018 Global Healthcare Conference 14-15 November...
Nordic Nanovector $NANO.OL pushing above NOK68 resistance on significant volume, closing at strong 70.3 before weekend. This indicates another attempt at breaking out of long time downtrend that has been effect since ATH back in december 2016.
Investors are seemingly very satisified with recent Q3 report and #ASH18 abstracts presented by CEO Eduardo Bravo and his...
Nordic Nanovector retraced from recent high to fill gaps down to support at NOK 48, which triggered a strong reversal pattern.
Investors will be keen to follow if the stock establishes a trading range above 53 NOK which would represent a breakout from the recent downtrend, and even more if the stock could possibly break free from the almost two year...
Omeros has been consolidating after breaking out of its long downtrend, but looks set to make a new attempt to move upwards, coinciding with a strong move in the $BB etf.
Needs volume of trade to confirm this move, while investors are waiting for a list of catalysts to trigger interest.
Omeros has been through a rough patch with shortsellers in full control, coming down from a swinging high last year.
With recent good news on several fronts, $OMER is trading well above longtrend, and looking to fully confirm breakout.
Top 50 shareholders list has only shown fairly minor changes during recent share price turmoil, but huge retail following were delighted to see Nordic Nanovector finally land approval to go ahead with PARADIGME pivotal clinical study. NANO spikes back 23.99%.
One interesting factor is the substantial gap between 63 and 68 NOK, with more positive news coming the...